Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBIAT (2016 - 2021)

Historic EBIAT for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $22.5 million.

  • Neurocrine Biosciences' EBIAT rose 13906.25% to $22.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $444.8 million, marking a year-over-year increase of 37623.13%. This contributed to the annual value of $407.3 million for FY2020, which is 100081.08% up from last year.
  • Neurocrine Biosciences' EBIAT amounted to $22.5 million in Q3 2021, which was up 13906.25% from $42.3 million recorded in Q2 2021.
  • Neurocrine Biosciences' EBIAT's 5-year high stood at $347.9 million during Q4 2020, with a 5-year trough of -$102.1 million in Q1 2019.
  • Over the past 5 years, Neurocrine Biosciences' median EBIAT value was $22.5 million (recorded in 2021), while the average stood at $22.1 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' EBIAT plummeted by 30659.26% in 2017, and later skyrocketed by 96757.99% in 2019.
  • Quarter analysis of 5 years shows Neurocrine Biosciences' EBIAT stood at $6.9 million in 2017, then soared by 162.23% to $18.1 million in 2018, then skyrocketed by 88.07% to $34.0 million in 2019, then skyrocketed by 923.24% to $347.9 million in 2020, then plummeted by 93.53% to $22.5 million in 2021.
  • Its EBIAT was $22.5 million in Q3 2021, compared to $42.3 million in Q2 2021 and $32.1 million in Q1 2021.